Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice-daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma

Source: International Congress 2022 – Clinical treatment of asthma

Session: Clinical treatment of asthma
Session type: Thematic Poster
Number: 3858

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Chapman (Toronto (ON), Canada), R. Van-Zyl Smit (Cape Town, South Africa), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), H. Kerstjens (Groningen, Netherlands). Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice-daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma. 3858

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
• Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study